IP Library Patent Application 18117917
Patent Application
App. No. 18/117,917

SYSTEMS AND METHOD FOR DELIVERY OF THERAPEUTIC GAS TO PATIENTS, IN NEED THEREOF, RECEIVING BREATHING GAS FROM A VENTILATOR THAT VARIES AT LEAST PRESSURE AND/OR FLOW USING ENHANCED THERAPEUTIC GAS (NO) FLOW MEASUREMENT

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/117,917
Abstract

The present disclosure generally relates to systems and methods for delivery of therapeutic gas to patients, in need thereof, receiving breathing gas from a high frequency ventilator using at least enhanced therapeutic gas (e.g., nitric oxide, NO, etc.) flow measurement. At least some of these enhanced therapeutic gas flow measurements can be used to address some surprising phenomenon that may, at times, occur when wild stream blending therapeutic gas into breathing gas a patient receives from a breathing circuit affiliated with a high frequency ventilator. Utilizing at least some of these enhanced therapeutic gas flow measurements the dose of therapeutic gas wild stream blended into breathing gas that the patient receives can at least be more accurate and/or under delivery of therapeutic gas into the breathing gas can be avoided and/or reduced.

Claims (52)

1 . A method of delivering nitric oxide gas to a patient in need thereof, the method comprising:

providing, through at least one control valve of a nitric oxide delivery system, a flow of nitric oxide gas to an injector module configured to inject the nitric oxide gas into a breathing gas in an inspiratory limb of a breathing circuit affiliated with a high frequency ventilator or ventilation techniques which provide reverse and/or oscillations in inspiratory pressure or flow;

measuring, using at least one NO flow sensor, NO flow, wherein the at least one NO flow sensor is in fluid communication with a therapeutic gas inlet of the injector module;

receiving, using a control system in communication with the at least one NO flow sensor, flow information from the at least one NO flow sensor; and

delivering the nitric oxide gas to the patient.

2 . The method of claim 1 , wherein the injector module has an injector body having a first opening and a second opening, the first opening and the second opening being configured to couple the injector module to the inspiratory limb of the breathing circuit enabling the breathing gas in the breathing circuit to flow through the first opening and the second opening.

3 . The method of claim 2 , wherein the therapeutic gas inlet is in the injector body, the therapeutic gas inlet being configured to receive the flow of the nitric oxide gas and enable injection of the nitric oxide gas into the injector module, and in turn into the breathing gas in the inspiratory limb of the breathing circuit.

4 . The method of claim 1 , wherein the control system is operable to:

(i) detect use of the high frequency ventilator;

(ii) identify the flow information as missing and interpolate the missing flow information; and/or (iii) identify the flow information as reverse flow.

5 . The method of claim 1 , wherein the therapeutic gas inlet receives the flow of nitric oxide gas from a nitric oxide source, via a conduit.

6 . The method of claim 5 , wherein the nitric oxide source is a cylinder storing NO or an NO generator.

7 . The method of claim 6 , further comprising generating the nitric oxide gas by reaction of a NO-releasing agent with a reductant using the NO generator.

8 . The method of claim 7 , wherein the NO-releasing agent is nitrogen dioxide and the reductant is ascorbic acid.

9 . The method of claim 1 , further comprising monitoring the flow information, using the control system, to ensure that a desired dose of NO is delivered into the injector module, and in turn into the breathing gas in the inspiratory limb of the breathing circuit.

10 . The method of claim 1 , furthering comprising monitoring the flow information, using the control system, to ensure a desired does of NO is not under delivered and/or under dosed.

11 . The method of claim 1 , further comprising opening or closing a check valve that is one or more of (i) in fluid communication with the therapeutic gas inlet of the injector module and (ii) is integral to the injector module.

12 . The method of claim 1 , wherein the at least one NO flow sensor is at least one bi-directional flow sensor.

13 . The method of claim 12 , wherein the at least one bi-directional flow sensor is a thermal mass flow meter or a thermal dispersion flow meter.

14 . The method of claim 1 , wherein the inspiratory limb is also an expiratory limb in the breathing circuit.

15 . The method of claim 1 , wherein the NO flow sensor is downstream of the control valve in the nitric oxide delivery system.

16 . The method of claim 1 , wherein the control valve is upstream of the NO flow sensor in the nitric oxide delivery system.

17 . The method of claim 1 , further comprising receiving the flow of nitric oxide gas at the therapeutic gas inlet via a conduit, wherein the conduit has one or more of (i) an internal cross-sectional diameter of about 1/32 of an inch to about ¼ of an inch and (ii) an internal portion within the nitric oxide delivery system and an external portion outside the nitric oxide delivery system, the internal portion of the conduit having a cross-sectional diameter that is substantially the same as a cross-sectional diameter of the external portion of the conduit.

18 . The method of claim 1 , further comprising:

measuring, using at least a second NO flow sensor, NO flow, wherein the second NO flow sensor is in fluid communication with the therapeutic gas inlet and in communication with the control system,

receiving, at the control system, flow information from the second NO flow sensor; and

detecting, using the control system, a leak when the flow information from the NO flow sensors does not match.

19 . The method of claim 18 , further comprising increasing the flow of nitric oxide gas if a leak is detected.

20 . A method of delivering nitric oxide gas to a patient in need thereof, the method comprising:

providing, through a conduit and at least one control valve of a nitric oxide delivery system, a flow of nitric oxide gas to a therapeutic gas inlet of an injector module from a nitric oxide gas source, wherein the nitric oxide is injected into a breathing gas in an inspiratory limb of a breathing circuit affiliated with a high frequency ventilator or ventilation techniques which provide reverse and/or oscillations in inspiratory pressure or flow;

measuring, using at least one bi-directional NO flow sensor, NO flow in a forward direction and in a reverse direction through the therapeutic gas inlet, wherein the at least one bi-directional NO flow sensor is in fluid communication with the therapeutic gas inlet;

receiving, using a control system in communication with the at least one bi-directional NO flow sensor, bi-directional flow information; and

delivering the nitric oxide gas to the patient.

21 . The method of claim 20 , wherein the injector module has an injector body having a first opening and a second opening, the first opening and the second opening being configured to couple the injector module to the inspiratory limb of the breathing circuit enabling the breathing gas in the breathing circuit to flow through the first opening and the second opening.

22 . The method of claim 21 , wherein the therapeutic gas inlet is in the injector body, the therapeutic gas inlet being configured receive the flow of the nitric oxide gas and enable injection of the nitric oxide gas into the injector module, and in turn into the breathing gas in the inspiratory limb of the breathing circuit.

23 . The method of claim 20 , wherein the bi-directional flow information comprises at least forward flow information and reverse flow information.

24 . The method of claim 20 , wherein the nitric oxide source is a cylinder storing NO or an NO generator.

25 . The method of claim 24 , further comprising generating the nitric oxide gas by reaction of a NO-releasing agent with a reductant using the NO generator.

26 . The method of claim 25 , wherein the NO-releasing agent is nitrogen dioxide and the reductant is ascorbic acid.

27 . The method of claim 20 , further comprising monitoring the flow information, using the control system, to ensure that a desired dose of NO is delivered into the injector module, and in turn into patient breathing gas in the inspiratory limb of the breathing circuit.

28 . The method of claim 20 , further comprising monitoring the flow information, using the control system, to ensure that a desired dose of NO is not under delivered and/or under dosed.

29 . The method of claim 20 , further comprising opening or closing a check valve that is one or more of (i) in fluid communication with the therapeutic gas inlet of the injector module and (ii) is integral to the injector module.

30 . The method of claim 20 , wherein the at least one bi-directional flow sensor is a thermal mass flow meter or a thermal dispersion flow meter.

31 . The method of claim 20 , wherein the inspiratory limb is also an expiratory limb in the breathing circuit.

32 . The method of claim 20 , wherein the NO flow sensor is downstream of the control valve in the nitric oxide delivery system.

33 . The method of claim 20 , wherein the control valve is upstream of the NO flow sensor in the nitric oxide delivery system.

34 . The method of claim 20 , wherein the conduit has one or more of (i) an internal cross-sectional diameter of about 1/32 of an inch to about ¼ of an inch and (ii) an internal portion within the nitric oxide delivery system and an external portion outside the nitric oxide delivery system, the internal portion of the conduit having a cross-sectional diameter that is substantially the same as a cross-sectional diameter of the external portion of the conduit.

35 . The method of claim 20 , further comprising:

measuring, using at least a second bi-directional NO flow sensor, NO flow, wherein the second bi-directional flow sensor is in fluid communication with the therapeutic gas inlet and in communication with the control system,

receiving, at the control system, flow information from the second bi-directional NO flow sensor; and

detecting, using the control system, a leak when the flow information from the NO flow sensors does not match.

36 . The method of claim 35 , further comprising increasing the flow of nitric oxide gas if a leak is detected.

Assignments (13)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF US PATENT 10828415 AND REMOVE IT FROM THE LISTING PREVIOUSLY RECORDED ON REEL 72331 FRAME 1. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Mar 6, 2026
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 075021/0204 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF US PATENT 10828415 AND REMOVE IT FROM THE LISTING PREVIOUSLY RECORDED ON REEL 73375 FRAME 395. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Mar 6, 2026
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 075021/0263 →
SECURITY INTEREST Recorded Oct 28, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: GOLDMAN SACHS BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 073375/0395 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2025
From: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 072040/0424 →
CHANGE OF NAME Recorded Aug 16, 2025
From: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED
To: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY
Reel/Frame 072477/0834 →
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
SECURITY INTEREST Recorded Aug 1, 2025
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 072331/0001 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 064709, FRAME 0055 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0860 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 064709/FRAME 0111 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; SPECGX LLC; STRATATECH CORPORATION; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0308 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
SECURITY INTEREST Recorded Aug 25, 2023
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT LLC; STRATATECH CORPORATION; OCERA THERAPEUTICS, INC.; SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 064709/0111 →
SECURITY INTEREST Recorded Aug 25, 2023
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT LLC; STRATATECH CORPORATION; OCERA THERAPEUTICS, INC.; SPECGX LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 064709/0070 →
SECURITY INTEREST Recorded Aug 25, 2023
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT LLC; STRATATECH CORPORATION; OCERA THERAPEUTICS, INC.; SPECGX LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 064709/0055 →